Similar articles for PMID: 23956067

Year	Number of Results
2007	1
2008	6
2009	3
2010	9
2011	14
2012	15
2013	15
2014	17
2015	19
2016	13
2017	13
2018	7
2019	8
2020	7
2021	10
2022	4
2024	0

1

Initial testing (stage 1) of the Polo-like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical Testing Program.

Gorlick R, Kolb EA, Keir ST, Maris JM, Reynolds CP, Kang MH, Carol H, Lock R, Billups CA, Kurmasheva RT, Houghton PJ, Smith MA. Gorlick R, et al. Pediatr Blood Cancer. 2014 Jan;61(1):158-64. doi: 10.1002/pbc.24616. Epub 2013 Aug 19. Pediatr Blood Cancer. 2014. PMID: 23956067 Free PMC article.

2

Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Maris JM, Morton CL, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Wu J, Smith MA, Houghton PJ. Maris JM, et al. Pediatr Blood Cancer. 2010 Jul 15;55(1):26-34. doi: 10.1002/pbc.22430. Pediatr Blood Cancer. 2010. PMID: 20108338 Free PMC article.

3

Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.

Abbou S, Lanvers-Kaminsky C, Daudigeos-Dubus E, LE Dret L, Laplace-Builhe C, Molenaar J, Vassal G, Geoerger B; within the ITCC Biology and Preclinical Evaluation Committee. Abbou S, et al. Anticancer Res. 2016 Feb;36(2):599-609. Anticancer Res. 2016. PMID: 26851014

4

Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.

Cholewa BD, Ndiaye MA, Huang W, Liu X, Ahmad N. Cholewa BD, et al. Cancer Lett. 2017 Jan 28;385:179-187. doi: 10.1016/j.canlet.2016.10.025. Epub 2016 Oct 25. Cancer Lett. 2017. PMID: 27793694 Free PMC article.

5

Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinases, in preclinical models of acute myeloid leukemia.

Rudolph D, Impagnatiello MA, Blaukopf C, Sommer C, Gerlich DW, Roth M, Tontsch-Grunt U, Wernitznig A, Savarese F, Hofmann MH, Albrecht C, Geiselmann L, Reschke M, Garin-Chesa P, Zuber J, Moll J, Adolf GR, Kraut N. Rudolph D, et al. J Pharmacol Exp Ther. 2015 Mar;352(3):579-89. doi: 10.1124/jpet.114.221150. Epub 2015 Jan 9. J Pharmacol Exp Ther. 2015. PMID: 25576074

6

In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.

Van den Bossche J, Deben C, De Pauw I, Lambrechts H, Hermans C, Deschoolmeester V, Jacobs J, Specenier P, Pauwels P, Vermorken JB, Peeters M, Lardon F, Wouters A. Van den Bossche J, et al. Mol Oncol. 2019 May;13(5):1196-1213. doi: 10.1002/1878-0261.12477. Epub 2019 Apr 5. Mol Oncol. 2019. PMID: 30859681 Free PMC article.

7

Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor.

Van den Bossche J, Lardon F, Deschoolmeester V, De Pauw I, Vermorken JB, Specenier P, Pauwels P, Peeters M, Wouters A. Van den Bossche J, et al. Med Res Rev. 2016 Jul;36(4):749-86. doi: 10.1002/med.21392. Epub 2016 May 3. Med Res Rev. 2016. PMID: 27140825 Review.

8

A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.

Lin CC, Su WC, Yen CJ, Hsu CH, Su WP, Yeh KH, Lu YS, Cheng AL, Huang DC, Fritsch H, Voss F, Taube T, Yang JC. Lin CC, et al. Br J Cancer. 2014 May 13;110(10):2434-40. doi: 10.1038/bjc.2014.195. Epub 2014 Apr 22. Br J Cancer. 2014. PMID: 24755882 Free PMC article. Clinical Trial.

9

Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.

Wang Y, Singh R, Wang L, Nilsson M, Goonatilake R, Tong P, Li L, Giri U, Villalobos P, Mino B, Rodriguez-Canales J, Wistuba I, Wang J, Heymach JV, Johnson FM. Wang Y, et al. Oncotarget. 2016 Jul 26;7(30):47998-48010. doi: 10.18632/oncotarget.10332. Oncotarget. 2016. PMID: 27384992 Free PMC article.

10

Radiosensitization in esophageal squamous cell carcinoma: Effect of polo-like kinase 1 inhibition.

Chen JL, Chen JP, Huang YS, Tsai YC, Tsai MH, Jaw FS, Cheng JC, Kuo SH, Shieh MJ. Chen JL, et al. Strahlenther Onkol. 2016 Apr;192(4):260-8. doi: 10.1007/s00066-016-0951-6. Epub 2016 Mar 7. Strahlenther Onkol. 2016. PMID: 26952039

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

128 results

Results by year